Document Detail

Pharmaceutical care in medical progressive care patients.
MedLine Citation:
PMID:  9533058     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To develop, implement, and assess the outcomes of a system for providing pharmaceutical care to medical progressive care patients. METHODS: A system for providing pharmaceutical care was developed and implemented for an 8-week period beginning in June 1995. Both patient care outcomes and drug therapy cost change from the intervention period were compared with those of an 8-week baseline period. Variables compared included unit length of stay, hospital length of stay, transfers to the intensive care unit, readmissions, and adverse drug reactions requiring treatment. Differences between periods for these variables were assessed by using chi 2 tests and t-tests with alpha set at p less than 0.05. The clinical significance of the interventions were assessed independently by four physicians: two intensivists and two internists. The total drug therapy cost change from the intervention period was calculated as follows: total cost avoidance from individual recommendations subtracted from the total cost incurred from individual recommendations. RESULTS: The pharmacist evaluated 152 patients during the intervention period. A total of 235 pharmacotherapy recommendations were made on 103 patients, of whom 86.4% were accepted. Significantly fewer adverse drug reactions (ADRs) received treatment during the intervention period (p = 0.027). The mean unit length of stay was lower during the intervention period (4.8 +/- 3.7 d) than during the baseline period (6.0 +/- 5.6 d); however, this difference was not significant (p = 0.053). Individual physician assessment of the pharmacists' recommendations revealed that 75.8% were considered somewhat significant, significant, or very significant. The total drug therapy cost change from the intervention period was -$6534.53. The projected annual drug therapy cost reduction from this study is $42,474.45. CONCLUSIONS: The provision of pharmaceutical care to medical progressive care patients was associated with a substantial decrease in drug therapy cost and a decrease in the number of ADRs that required treatment.
M A Smythe; P P Shah; T L Spiteri; R L Lucarotti; R L Begle
Related Documents :
7970468 - The cost-effectiveness of prenatal carrier screening for cystic fibrosis.
22711378 - Conversion rates and perceived barriers to referral: views of extended scope physiother...
9431798 - Negotiating managed care and capitated contracts to minimize risks.
7649468 - Psychosocial care in the pediatric hospital. the need for scientific validation of clin...
17472498 - Go wish: a tool for end-of-life care conversations.
15186568 - The use of infrared thermometry for the detection of fever.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The Annals of pharmacotherapy     Volume:  32     ISSN:  1060-0280     ISO Abbreviation:  Ann Pharmacother     Publication Date:  1998 Mar 
Date Detail:
Created Date:  1998-05-08     Completed Date:  1998-05-08     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9203131     Medline TA:  Ann Pharmacother     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  294-9     Citation Subset:  IM    
Department of Pharmaceutical Services, William Beaumont Hospital, Royal Oak, MI, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Critical Care / economics
Delivery of Health Care
Drug Therapy / economics*
Length of Stay / statistics & numerical data
Outcome Assessment (Health Care)
Progressive Patient Care / economics*

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Surgical treatment. Total knee arthroplasty.
Next Document:  Comparison of phenytoin serum concentrations in premature neonates following intravenous and oral ad...